The document announces IMS Health's activities and presence at the ISPOR 7th Asia-Pacific Conference from September 3-6, 2016 in Singapore. IMS Health will host a symposium on how real-world evidence can enable pharmaceutical companies to partner in healthcare delivery. They will also participate in workshops, presentations, and have a booth showcasing their real-world evidence solutions and oncology research bibliography. IMS Health utilizes real-world data from electronic health records and claims to generate real-world evidence on drug safety and effectiveness to inform healthcare decisions.

1. ISPOR 7th Asia-Pacific Conference
3-6 September 2016, Singapore
Join us for the IMS Health Symposium
“How real-world evidence (RWE) can enable
pharma to partner in healthcare delivery”
Meet the largest expert community in RWE
Discover the findings from our latest research
IMS Health Real-World Evidence Solutions
at ISPOR, Singapore, September 2016

2. Live Sessions
with IMS Health
2
IMS Health invites you to join us for a compelling program of activities at the ISPOR
7th Asia-Pacific Conference. With demand for real-world evidence (RWE) growing
fast across the region, we are excited to share our perspective on the innovative
approaches that will be key to strengthening its creation and value going forward.
Reflecting our commitment to bringing insights from real-world data (RWD) to improve decision
making and patient outcomes, our research contributions at ISPOR demonstrate its power and
potential to inform healthcare issues in countries throughout Asia Pacific.
An overview of our symposium, workshops, posters and panel participation at the event can be found
in this brochure. Members of our global, regional and local RWE Solutions team will be on hand right
through, at the IMS Health booth (32–33).
We look forward to seeing you in Singapore!
Welcome to IMS Health at ISPOR, Singapore
Pre-Conference Short Courses
•Patient-reported outcomes measures (PROMs):
Cross-cultural development
and validation
3 September, 13:00–17:00
•Health care systems in Asia
4 September, 08:00–12:00
Educational Symposium
•How real-world evidence (RWE) can enable
pharma to partner in healthcare delivery
5 September, 13:15–14:15
Workshops
•Value proposition development: Communicating
value in the patients’ language
4 September, 17:00–18:00
•Introducing a novel concept to observational
research in the Asia-Pacific region: Enriched
real-world data studies
6 September, 16:00–17:00
ISPOR Forum
•Big data in Asia-Pacific – a valuable resource
for better healthcare decisions: Experiences
and lessons learned in Australia, Japan,
Singapore, South Korea and Taiwan
6 September, 08:30–09:30
See pages 3–6 for further details
ISPOR 7th Asia-Pacific Conference, 3-6 September 2016, Singapore

3. 3
IMS Health Symposium Monday, 5 September
“How real-world evidence (RWE) can enable pharma to partner in healthcare delivery”
RWE is increasingly prominent on the global stage, helping pharmaceutical manufacturers, reimbursement
decision makers, HTA organizations and clinicians better understand diseases, patient treatment and outcomes.
Yet it is just at an early stage in Asia Pacific and given its current state compared to the USA or European
markets, there is an increasing sense of urgency to find ways of developing useful RWE in this region.
Decision makers are seeking more evidence to support their assessments, putting greater pressure on the
industry to develop re-usable data infrastructures and novel approaches to data generation, and work
more collaboratively to help integrate disparate data while maintaining patient privacy.
This symposium will provide an overview of the need for RWE and availability of RWD in Asia Pacific today
but focus on advances and methodologies that would help companies generate more RWE in the region.
Innovative approaches include partnerships involving and aligning different healthcare stakeholders as
well as “mosaic” and enriched approaches.
Discussing these issues, our panel will include senior representatives from the pharmaceutical industry
and research institutions as well as experts from IMS Health.
Agenda
Introduction: The increasing need for RWE in Asia Pacific 13:15–13:20
Bruce Crawford, MA, MPH (Chair), Senior Principal, RWE Solutions, Japan & APAC, IMS Health, Tokyo, Japan
Growing demand for evidence by payers in Asia: An industry perspective on possible ways forward to create
RWE in the region 13:20–13:35
Aileen Dualan, MD, MS, Chief Scientific Officer, Asia Cluster, Novartis Asia Pacific Pharmaceuticals, Singapore
Novel partnership approaches to generate RWE across Asia Pacific 13:35–13:50
Christopher J. King, MBA, Oncology Head, APAC, IMS Health, Singapore
Innovative methodological approaches to enrich existing data assets in Asia Pacific 13:50–14:05
Karen Wai, MB BCh BAO, MBA, VP, Regional Managing Director, Real-World & Late Phase Research Asia Pacific,
Quintiles, Singapore
Moderated Q&A 14:05–14:15
Bruce Crawford, MA, MPH (Chair)
Proceedings from the symposium can be obtained from IMS Health.
To receive a copy, please email Angelika Boucsein at Aboucsein@de.imshealth.com
IMS Health Real-World Evidence Solutions

4. 4ISPOR 7th Asia-Pacific Conference, 3-6 September 2016, Singapore
Symposium Panel
Bruce Crawford, MA, MPH is Senior Principal, Real-World Evidence Solutions, Japan and Asia Pacific &
China, at IMS Health in Tokyo. He has more than 20 years of consulting experience and expertise in
prospective study design, patient-reported outcome evaluations, cost-effectiveness analyses and
reimbursement, and has worked on projects throughout Asia for the last 13 years. Bruce was previously
Managing Director Asia and Senior VP at Adelphi, prior to which he served as Operations Director at Mapi
Values. He has also worked in Managed Care and for a major CRO as a health economist, as well as being
involved in research and training with the US FDA, the Japanese PMDA, and the Thailand FDA and National List
of Essential Drugs Committee. Bruce has written and lectured on pharmacoeconomic and outcomes research
methodologies and impacts on study validity, and held appointments as Adjunct Project Professor of HTA and
Public Policy at Tokyo University Graduate School of Public Policy and as Adjunct Instructor at Kyoto University
School Of Medicine and Public Health, Department of Pharmacoepidemiology.
Aileen Dualan, MD, MS is Chief Scientific Officer, Asia at Novartis Pharmaceuticals in Singapore, where
she has been working since 2013. She is also President of APMS, the Association of Pharmaceutical Medicine
(Singapore), a role she assumed in 2015. Dr. Dualan has 13 years of experience in the pharmaceutical industry.
She has been based in Singapore since 2010, serving in various regional medical roles. Prior to this she held
positions in medical affairs, development and pharmacovigilance in the Philippines. Dr. Dualan’s experience
before joining the industry was heavily focused on research and academics. A board certified pediatrician, she
was admitted as a Diplomate of the American Board of Pediatrics in 1997. She is currently a PhD candidate in
Epidemiology, having further supported her endeavors in the corporate world by obtaining a Certificate of
Business Leadership in 2006 and more recently a Certification in Health Economics.
Christopher J. King, MBA is Oncology Head, Asia Pacific & China at IMS Health in Singapore, where he
leads the direction of next-generation RWE offerings and services and is the therapeutic expert for oncology-
related consulting engagements in the region. He has expertise in RWE strategic solutions, commercial product
forecast modeling, market and product assessments, and product positioning/launch strategy. Prior to joining
IMS Health, Chris was Head of the European Oncology Monitor at Ipsos, responsible for product development,
team leadership, staff management and client servicing for its European Oncology Monitor business. He was
previously with the Healthcare Consulting practice at DataMonitor, working on various global strategic
pharmaceutical and biotech consultancy projects covering major as well as emerging markets. Chris also has
clinical research experience, gained at the British Columbia Cancer Research Centre where he was responsible
for database design and implementation, quality control and statistics.
Karen Wai, MB BCh BAO, MBA is VP, Regional Managing Director, Real-World & Late Phase Research
Asia Pacific, at Quintiles in Singapore, leading a team that delivers innovative solutions in this space in the
region. A physician by training and an experienced medical and pharmaceutical healthcare expert, she has
served as Medical and Scientific Advisor for more than 60 clinical trial protocols in oncology, neurology,
cardiovascular, anti-infective and rheumatoid arthritis indications. Dr. Wai has leveraged her medical and
safety background to continue her career enhancing efficiency and quality during clinical trial planning, and
built relationships with multiple investigators and physicians around the globe and, in particular, the Asia-
Pacific region. She is also passionate about engaging the patient throughout the product or device lifecycle.
Prior to joining Quintiles, Dr. Wai worked as a physician in both the public and private healthcare sector. She
has direct management and operational experience in European, African and Asian environments.

5. 5
IMS Health Activities 3-5 September
3SEPTEMBER4SEPTEMBER5SEPTEMBER
CODE TOPIC PRESENTERS TYPE
PATIENT-REPORTED OUTCOMES MEASURES (PROMS):
CROSS-CULTURAL DEVELOPMENT AND VALIDATION
Crawford B, Lin Wee H
Pre-
Conference
Short Course
HEALTH CARE SYSTEMS IN ASIA Yang B-M , Crawford B, Zhao K,
Sharma J
Pre-
Conference
Short Course
W5 VALUE PROPOSITION DEVELOPMENT: COMMUNICATING VALUE IN
THE PATIENTS’ LANGUAGE
Crawford B, Wada K, Caputo J,
Leartsakulpanitch J
Workshop
PHP112 LOCAL UTILITIES FOR LOCAL STUDIES: DATA AVAILABILITY AND
METHODOLOGY IN JAPAN AND KOREA
Kim HR, Chen X, Pyo J,
Crawford B
Research
Poster
PMH18 THE MEDICATION ADHERENCE IN SCHIZOPHRENIA MANAGEMENT BY USING
SECOND GENERATION ANTIPSYCHOTICS IN TAIWAN: A POPULATION STUDY
BASED ON NHRID
Chung C, Tai TA, Chou KP Research
Poster
PSS1 LONG-TERM FOLLOW-UP OF RANIBIZUMAB TREATED PATIENTS WITH MYOPIC
CHOROIDAL NEOVASCULARIZATION FROM THE RADIANCE CLINICAL TRIAL IN
FOUR EAST ASIAN COUNTRIES
Skelly A, Lara N, Pedros M,
Macfadden W
Research
Poster
HOW REAL-WORLD EVIDENCE (RWE) CAN ENABLE PHARMA TO PARTNER IN
HEALTHCARE DELIVERY
Crawford B, Dualan A, King CJ,
Wai K
Educational
Symposium
PRM20 FEASIBILITY OF ELECTRONIC MEDICAL RECORDS IN AUSTRALIA, CHINA, AND
JAPAN TO SUPPORT NOVELTY (A NOVEL OBSERVATIONAL LONGITUDINAL
STUDY OF PATIENTS WITH ASTHMA AND/OR COPD)
Wang X, Gerhardsson de Verdier M,
Sveréus A, Hiller J, Wong D,
Nasuti P, Jenner H, McKenney A
Research
Poster
PRS9 COPD UNCOVERED: HEALTH CARE RESOURCE USE AND COST OF CHRONIC
OBSTRUCTIVE PULMONARY DISEASE IN JAPAN
Igarashi A, Fukuchi Y, Hirata K,
Ichinose M, Nagai A, Nishimura M,
Lara N, Murata S, Gruenberger J
Research
Poster
PSY3 THE IMPACT OF MEDICAL INSURANCE COVERAGE OF IMATINIB AND
MOLECULAR MONITORING FREQUENCY ON OUTCOMES IN TREATMENT OF
CHRONIC MYELOID LEUKAEMIA (CML): REAL-WORLD EVIDENCE IN CHINA
Chen S, Sheng G, Zhang R, Miao M,
Wu D, Xiong T, Tan SC, Liu C
Research
Poster
PSY13 SOCIETAL IMPLICATIONS OF MEDICAL INSURANCE COVERAGE FOR IMATINIB
AS FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKAEMIA IN CHINA:
A COST EFFECTIVENESS ANALYSIS
Chen S, Dong C, Sheng G,
Zhang R, Miao M, Wu D, Xiong T,
Tan SC, Liu C
Research
Poster
IMS Health Real-World Evidence Solutions

6. 6SEPTEMBER
6
IMS Health Activities 6 September
F3 BIG DATA IN ASIA-PACIFIC – A VALUABLE RESOURCE FOR BETTER HEALTHCARE
DECISIONS: EXPERIENCES AND LESSONS LEARNED IN AUSTRALIA, JAPAN,
SINGAPORE, SOUTH KOREA, AND TAIWAN
Roughead L, Crawford B,
Lin Wee H, Bae SJ, Chang CJ
ISPOR
Forum
W12 INTRODUCING A NOVEL CONCEPT TO OBSERVATIONAL RESEARCH IN THE
ASIA-PACIFIC REGION: ENRICHED REAL-WORLD DATA STUDIES
Garcia Alvarez L, Hiller J, Yoong J,
Leong Seng O
Workshop
PCN32 COST-EFFECTIVENESS ANALYSIS OF OXALIPLATIN PLUS
FLUOROURACIL/LEUCOVORIN (FOLFOX4) COMPARED TO SORAFENIB FOR
TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN CHINA
Qin SK, Kruger E, Tan SC,
Cheng SQ, Yao XX, Liang J
Research
Poster
PCN46 PATIENT-REPORTED OUTCOMES IN JAPANESE ONCOLOGY PRODUCTS -
REVIEW OF THE PMDA LABELS
Crawford B, Kim HR Research
Poster
PDB19 THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN
PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
Lin H, Babineaux S, Lew T, Lowin J,
Lovato E, Strizek AA, Rajan N
Research
Poster
PMS4 THE COMPARISONS OF BIOLOGICS WITH METHOTREXATE FOR TREATING
RHEUMATOID ARTHRITIS PATIENTS IN TAIWAN: THE USE OF COST-UTILITY
ANALYSIS AND BUDGET IMPACT ANALYSIS
Li C, Chou P, Chang C, Fann CS Research
Poster
IMS Health Real-World Evidence Solutions Bibliography
Our research expertise and therapy area knowledge are
captured in more than 3,500 publications, spanning
virtually all therapy areas and projects completed in over
50 countries worldwide.
A special IMS Health RWE Solutions Oncology Bibliography will be
available at ISPOR. This captures our wide range of HEOR and RWE
papers and presentations published since 2010 across a variety of solid
and hematological cancers globally. Pick up your copy at our booth to
discover the research topics and innovative methodologies explored by
our experts and tumor-specific specialists to inform key challenges in
oncology today. To see our full database online, visit
www.imsrwebibliography.com.
CODE TOPIC PRESENTERS TYPE
ISPOR 7th Asia-Pacific Conference, 3-6 September 2016, Singapore
Oncology Bibliography
IMS Health Real-World Evidence Solutions
Published papers and presentationsin solid and hematological cancers2010–2016

7. 7
IMS Health Our Distinctive Approach
IMS Health has taken a holistic approach to RWE in pursuit of the most robust and
insightful views of patient outcomes. With the breadth and depth of our capabilities
we are uniquely positioned to generate and use RWE globally.
Applying the appropriate scientific and commercial lens and latest techniques to anonymous
RWD is critical to realizing the value of RWE in healthcare decisions.
IMS Health Real-World Evidence Solutions
IMS HEALTH
REAL-WORLD
EVIDENCE
SOLUTIONS
Real-World Data
Identify and access the most appropriate data sources while ensuring patient privacy
• The broadest and deepest collection of scientifically-validated, anonymous patient-level
data assets complemented by custom data sourcing
Technology-Enabled Analytics
Create consistent data models empowering analyses and leveraging innovative
technologies
• Extraction, analysis and visualization of RWD with IMS Health’s E360TM
technology suite
• Sophisticated data linkage and interpretation
Services and Engagement
Analyze RWD using scientific rigor, clear governance and advanced analytic and
processing capabilities
• Market Access & HTA
• Health Economics
• Outcomes Research
• Pharmacoepidemiology & Drug Safety
• Commercial Analytics
IMS Health can uniquely support all elements of the
RWE ecosystem – an environment where all the components
of RWE come together for a consistent, insightful view of
what really happens in healthcare. An environment which,
for the first time, helps all functions realize its potential.
Nurturing your real-world success

8. ©2016 IMS Health Incorporated and its affiliates. All rights reserved.
IMS HEALTH, IMS HEALTH INTELLIGENCE APPLIED and E360 are
trademarks of IMS Health Incorporated.
ORB1616
IMS Health Real-World Evidence Solutions
is based in 20 countries worldwide with regional headquarters in
RWEinfo@imshealth.com
www.imshealth.com/rwe
www.linkedin.com/company/ims-health-real-world-evidence
www.twitter.com/IMSHealthRWE
Europe
210 Pentonville Road
London N1 9JY
United Kingdom
Tel: +44 (0) 20 3075 4800
The Americas
485 Lexington Avenue
26th Floor
New York, NY 10017
USA
Tel: +1 646 596 6053
Latin America
Insurgentes Sur # 2375
5th Floor
Col. Tizapan
México D.F.- C.P. 01090
México
Tel: +52 55 5089 5205
Asia-Pacific & Japan
8 Cross Street #21-01/02/03
Singapore 048424
Singapore
Tel: +65 6412 7365
Toranomon Towers Office
4-1-28 Toranomon
Minato-ku
Tokyo 150-0001
Japan
Tel: +81 3 5425 9541
Our RWE experts will be running demonstrations of IMS Health
E360™ during ISPOR. This powerful suite of RWE applications
allows researchers to answer even the most challenging questions
in a standardized, intuitive way.
Book a demonstration of IMS Health’s E360™ technology suite
Schedule your individual demonstration at the IMS Health booth (32-33) or by emailing RWEinfo@imshealth.com